191 related articles for article (PubMed ID: 31240949)
1. Systematic Review of adverse events reporting in clinical trials leading to approval of targeted therapy and immunotherapy.
Bossi P; Botta L; Bironzo P; Sonetto C; Musettini G; Sbrana A; Di Giannantonio V; Locati LD; Di Maio M; Antonuzzo A
Future Oncol; 2019 Jul; 15(21):2543-2553. PubMed ID: 31240949
[No Abstract] [Full Text] [Related]
2. [Description of adverse events in publications of clinical trials: much room for improvement.].
Di Maio M; Antonuzzo A; Bossi P
Recenti Prog Med; 2019; 110(7):323-324. PubMed ID: 31379365
[TBL] [Abstract][Full Text] [Related]
3. Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials.
Unger JM; Vaidya R; Albain KS; LeBlanc M; Minasian LM; Gotay CC; Henry NL; Fisch MJ; Lee SM; Blanke CD; Hershman DL
J Clin Oncol; 2022 May; 40(13):1474-1486. PubMed ID: 35119908
[TBL] [Abstract][Full Text] [Related]
4. Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: a systematic review.
Péron J; Maillet D; Gan HK; Chen EX; You B
J Clin Oncol; 2013 Nov; 31(31):3957-63. PubMed ID: 24062406
[TBL] [Abstract][Full Text] [Related]
5. Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities.
Kanjanapan Y; Day D; Wang L; Al-Sawaihey H; Abbas E; Namini A; Siu LL; Hansen A; Razak AA; Spreafico A; Leighl N; Joshua AM; Butler MO; Hogg D; Chappell MA; Soultani L; Chow K; Boujos S; Bedard PL
Cancer; 2019 Apr; 125(8):1341-1349. PubMed ID: 30768786
[TBL] [Abstract][Full Text] [Related]
6. Perspectives in the treatment of pancreatic adenocarcinoma.
Cid-Arregui A; Juarez V
World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
[TBL] [Abstract][Full Text] [Related]
7. Analysis of adverse events attribution and reporting in cancer clinical trials: A systematic review.
Enrico D; Waisberg F; Burton J; Mandó P; Chacón M
Crit Rev Oncol Hematol; 2021 Apr; 160():103296. PubMed ID: 33675904
[TBL] [Abstract][Full Text] [Related]
8. Combinatorial approach to treatment of melanoma.
Ashworth MT; Daud AI
Hematol Oncol Clin North Am; 2014 Jun; 28(3):601-12. PubMed ID: 24880950
[TBL] [Abstract][Full Text] [Related]
9. Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review.
Kroeze SG; Fritz C; Hoyer M; Lo SS; Ricardi U; Sahgal A; Stahel R; Stupp R; Guckenberger M
Cancer Treat Rev; 2017 Feb; 53():25-37. PubMed ID: 28056412
[TBL] [Abstract][Full Text] [Related]
10. Treatment patterns of advanced malignant melanoma (stage III-IV) - A review of current standards in Europe.
Harries M; Malvehy J; Lebbe C; Heron L; Amelio J; Szabo Z; Schadendorf D
Eur J Cancer; 2016 Jun; 60():179-89. PubMed ID: 27118416
[TBL] [Abstract][Full Text] [Related]
11. Drug-related problems with targeted/immunotherapies at an oncology outpatient clinic.
Kucuk E; Bayraktar-Ekincioglu A; Erman M; Kilickap S
J Oncol Pharm Pract; 2020 Apr; 26(3):595-602. PubMed ID: 31342849
[TBL] [Abstract][Full Text] [Related]
12. Adverse events from targeted therapies in advanced renal cell carcinoma: the impact on long-term use.
Kirkali Z
BJU Int; 2011 Jun; 107(11):1722-32. PubMed ID: 21251188
[TBL] [Abstract][Full Text] [Related]
13. The FDA Oncology Center of Excellence and precision medicine.
Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
[TBL] [Abstract][Full Text] [Related]
14. Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology.
Grávalos C; Sanmartín O; Gúrpide A; España A; Majem M; Suh Oh HJ; Aragón I; Segura S; Beato C; Botella R
Clin Transl Oncol; 2019 May; 21(5):556-571. PubMed ID: 30284232
[TBL] [Abstract][Full Text] [Related]
15. The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer.
Santana-Davila R; Chow LQ
Future Oncol; 2018 Feb; 14(3):191-194. PubMed ID: 29334785
[No Abstract] [Full Text] [Related]
16. A systematic review of adverse event reporting in companion animal clinical trials evaluating cancer treatment.
Giuffrida MA
J Am Vet Med Assoc; 2016 Nov; 249(9):1079-1087. PubMed ID: 27767430
[TBL] [Abstract][Full Text] [Related]
17. Adverse Event Reporting Quality in Cancer Clinical Trials Evaluating Immune Checkpoint Inhibitor Therapy: A Systematic Review.
Wang Y; Chen C; Du W; Zhou Y; He L; Hong S; Zhang L
Front Immunol; 2022; 13():874829. PubMed ID: 35874673
[TBL] [Abstract][Full Text] [Related]
18. Revisiting Risk and Benefit in Early Oncology Trials in the Era of Precision Medicine: A Systematic Review and Meta-Analysis of Phase I Trials of Targeted Single-Agent Anticancer Therapies.
Mackley MP; Fernandez NR; Fletcher B; Woolcott CG; Fernandez CV
JCO Precis Oncol; 2021 Nov; 5():17-26. PubMed ID: 34994588
[TBL] [Abstract][Full Text] [Related]
19. The reporting of adverse events in oncology phase III trials: a comparison of the current status versus the expectations of the EORTC members.
Maillet D; Blay JY; You B; Rachdi A; Gan HK; Péron J
Ann Oncol; 2016 Jan; 27(1):192-8. PubMed ID: 26483049
[TBL] [Abstract][Full Text] [Related]
20. Cardiotoxicity in targeted therapy for breast cancer: A study of the FDA adverse event reporting system (FAERS).
Wittayanukorn S; Qian J; Johnson BS; Hansen RA
J Oncol Pharm Pract; 2017 Mar; 23(2):93-102. PubMed ID: 26661047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
